LENZ Therapeutics: Millennium reports potential 3.7% stake
The ownership attribution is qualified: the shares are held by entities, and the disclosure says it alone is not an admission of beneficial ownership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
LENZ Therapeutics, Inc. is the issuer for which Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, as reporting persons, each listed potential beneficial ownership of 1,159,987 shares, or 3.7% of the class. Each reported shared voting and dispositive power over 1,159,987 shares, with zero sole voting and dispositive power.
The disclosure says the shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. It states that the disclosure alone is not an admission of beneficial ownership by the reporting persons.
Key Figures
Key Terms
beneficially owned regulatory
Joint Filing Agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.